2 news items
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
17 May 24
, for the same period in 2023. Research and development expenses increased from $27.4 million to $30.7 million for the three months
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
million, as compared to $143.4 million, for the year ended December 31, 2022. Research and development expenses
- Prev
- 1
- Next